Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries
Lexaria Bioscience Corp WT
(NQ:
LEXXW
)
1.050
+0.050 (+5.00%)
Streaming Delayed Price
Updated: 10:32 AM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
15,138
Open
1.080
Bid (Size)
0.9500 (3)
Ask (Size)
1.050 (17)
Prev. Close
1.000
Today's Range
1.000 - 1.080
52wk Range
0.0500 - 2.500
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports Positive 8-Week Body Weight Results from Ongoing Diabetes Animal Study
August 22, 2024
Via
CannabisNewsWire
Topics
Intellectual Property
Exposures
Intellectual Property
Positive 8-Week Body Weight Results from Lexaria's GLP-1 Diabetes Animal Study
August 22, 2024
Via
ACCESSWIRE
Performance
YTD
+110.00%
+110.00%
1 Month
-4.55%
-4.55%
3 Month
-11.76%
-11.76%
6 Month
+23.54%
+23.54%
1 Year
+320.00%
+320.00%
More News
Read More
Positive Interim Blood Sugar Results from Lexaria's GLP-1 Diabetes Animal Study
August 21, 2024
Via
ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports on Positive Results from Molecular Characterization Study
August 19, 2024
Via
CannabisNewsWire
Topics
Regulatory Compliance
Exposures
Legal
Regulatory
Positive Results from Lexaria's Molecular Characterization Study
August 19, 2024
Via
ACCESSWIRE
Positive Interim Body Weight Results from Lexaria's Diabetes Animal Study
July 17, 2024
Via
ACCESSWIRE
Lexaria Preparing For Strategic Growth
July 16, 2024
Via
ACCESSWIRE
Dosing is Complete in Lexaria's Second GLP-1 Human Pilot Study
July 09, 2024
Via
ACCESSWIRE
Lexaria Receives New Patents For Antiviral Drug Delivery and for Treating Epilepsy
July 08, 2024
Via
ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Noteworthy Findings from Interim Results of Ongoing Diabetes Animal Study
July 17, 2024
Via
CannabisNewsWire
Topics
Intellectual Property
Exposures
Intellectual Property
Lexaria Awards CRO Contract for 12-Week DehydraTECH GLP-1 Chronic Human Study
June 18, 2024
Via
ACCESSWIRE
Dosing Continues in Lexaria’s Second GLP-1 Human Pilot Study
June 05, 2024
Via
ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Selects CRO in Third GLP-1 Human Pilot Study
May 23, 2024
Via
CannabisNewsWire
Topics
Intellectual Property
Exposures
Intellectual Property
Lexaria Awards Contract For Third GLP-1 Human Pilot Study
May 23, 2024
Via
ACCESSWIRE
Lexaria Receives Ethics Review Board Approval to Begin New GLP-1 Study
April 16, 2024
Via
ACCESSWIRE
Lexaria Receives Two New Medical-Treatment Patents in Hypertension and Epilepsy
May 21, 2024
Via
ACCESSWIRE
Dosing Begins in Lexaria's Comprehensive GLP-1 Animal Study
May 17, 2024
Via
ACCESSWIRE
Lexaria Begins Dosing of Its Second GLP-1 Human Pilot Study
May 08, 2024
Via
ACCESSWIRE
Lexaria Announces New Research Program to Evaluate Mode of Action and Performance of DehydraTECH-GLP-1 Drugs
May 06, 2024
Via
ACCESSWIRE
Lexaria to Receive $4.7 Million Gross Proceeds in Warrant Exercise and Issuance
April 30, 2024
Via
ACCESSWIRE
Lexaria Awarded New Patents
April 02, 2024
Via
ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Receives Approval to Commence Human Pilot Study Evaluating GLP-1, DehydraTECH
April 16, 2024
Via
CannabisNewsWire
Topics
Intellectual Property
Exposures
Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Names Experienced Corporate Finance Exec as New CFO
March 14, 2024
Via
CannabisNewsWire
Topics
Intellectual Property
Exposures
Intellectual Property
Lexaria Appoints Nelson Cabatuan as Chief Financial Officer
March 14, 2024
Via
ACCESSWIRE
Lexaria Awards Contract For Next GLP-1 Human Pilot Study
March 07, 2024
Via
ACCESSWIRE
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.